News
Unlocking sleep’s role in PTSD
In a groundbreaking study, Ben Vaughn, Rho’s Chief Strategist, Biostatistics & Protocol Design, explores how sleep disturbances impact posttraumatic stress disorder (PTSD). His research sheds light on a novel treatment, TNX-102 SL, which targets sleep quality and emotional memory processing. Discover the potential breakthrough in PTSD intervention in Psychiatry Research’s article: A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder.